Document:

EX-10.1

 Exhibit 10.1 

BOARD NOMINATION AGREEMENT 

This Board Nomination Agreement (this “Agreement”), dated as of December 10, 2014 (the “Effective
Date”), is by and among Authentidate Holding Corp., a Delaware corporation (the “Company”) and the persons and entities listed on Schedule A hereto (collectively, the “Lazarus
Group”, and individually a “member” of the Lazarus Group). 
 Unless otherwise specified herein, all of
the capitalized terms used herein are defined in Section 6 hereof. 
 WHEREAS, the Lazarus Group has filed an amendment to its
Schedule 13D on September 4, 2014, discussing certain understandings that the Lazarus Group has with respect to the composition of the Company’s Board of Directors (the “Board”); and 

WHEREAS, each of the Company and the Lazarus Group have determined that it is in their best interests to enter into this Agreement. 

NOW, THEREFORE, in consideration of and reliance upon the mutual covenants and agreements contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 
  

	Section 1.	Board Composition and Related Procedures. 

 (a) Subject to the terms and
conditions of this Agreement (including the provisions of Section 2(a)) and provided he is an Independent Director (as defined herein), the Board shall take all action reasonably necessary to appoint Marc A. Horowitz (the
“Lazarus Nominee”) to serve as a director of the Company until no earlier than the 2015 Annual Meeting and his successor is duly elected and qualified. 

(b) In connection with the agreement set forth in Section 1(a), the Company shall, subject to its rights under
Section 2: (i) if necessary to establish a vacancy on the Board, promptly increase the size of the Board by one (1) member and (ii) at all times during the Designation Period, include, and use its best efforts to cause the
Board, whether acting through the Company’s Nominating and Corporate Governance Committee of its Board of Directors (the “Nominating Committee”) or otherwise, to include the Lazarus Nominee in the slate of nominees
recommended to the stockholders of the Company for election as a director at any annual or special meeting of the stockholders held during the Designation Period (or, if permitted, by any action by written consent of the stockholders taken during
the Designation Period) at or by which directors of the Company are to be elected. 
 (c) If a Board vacancy occurs during the Designation
Period solely because of the death, disability, disqualification, resignation or removal of the Lazarus Nominee, the Lazarus Group shall be entitled to designate such person’s successor in accordance with the following conditions and compliance
with Section 2(b) of this Agreement. In the event the Lazarus Group has the right under this Section 1(c) to designate a successor to the initial Lazarus Nominee, the Lazarus Group shall have the right (subject to
Section 2(b) of this Agreement) to designate a reasonably qualified replacement for the Lazarus Nominee, with the consent of the Company (which consent shall not be unreasonably withheld or delayed), and the Company shall take all
necessary action to implement the foregoing as promptly as practicable. In connection with the foregoing, unless otherwise expressly agreed upon by the Company in writing, a successor nominee designated pursuant to this Section1(c), shall be
an Independent Director. Any such designated replacement who becomes a Board member shall be deemed to be a Lazarus Nominee for all purposes under this Agreement. 

  
 - 1 - 

 (d) If during the Designation Period the Lazarus Nominee is not nominated or elected to the
Board because of his or her death, disability, disqualification, withdrawal as a nominee or such Lazarus Nominee is for any other reason unavailable or unable to serve on the Board, the Lazarus Group shall be entitled to promptly designate another
nominee in accordance with the applicable provisions of Section 1(c) and Section 2(b) and the director position for which such Lazarus Nominee was nominated shall not be filled pending such designation. 

(e) The Lazarus Nominee shall be entitled to the same compensation paid and expense reimbursement payable to other non-employee Directors.

 (f) If in the reasonable judgment of the Company, the rights granted to the Lazarus Group under this Agreement, including the right to
elect or appoint the Lazarus Nominee, would cause the Company to not comply with the relevant listing rules of the Nasdaq Stock Market (the “Listing Rules”), including the requirement that the Company’s Board be
comprised of a majority of Independent Directors, then the Company may defer the appointment and/or election of such Lazarus Nominee, or take such other action (as the Board determines in the exercise of its discretion) as would enable the Company
to maintain compliance with the Listing Rules, until it is able to take commercially reasonable measures to ensure that the exercise by the Lazarus Group of its rights hereunder would not cause the Company to violate the Listing Rules. For the
purpose of clarity, it is agreed that such measures may include a further increase in the size of the Board and the appointment and/or election of one or more additional individuals to serve as an Independent Director, which individual(s) shall be
selected in the sole discretion of the Company. 
 (g) Notwithstanding the foregoing, if at any time after the date hereof, the Lazarus
Group, together with all Affiliates of the Lazarus Group (such Affiliates, collectively and individually, the “Lazarus Affiliates”), ceases collectively to Beneficially Own at least 20% of the Outstanding Equity, the Lazarus
Group shall cause the Lazarus Nominee to promptly tender his or her resignation from the Board and any committee of the Board on which he or she then sits. 

(h) Each Lazarus Nominee shall at all times while such Lazarus Nominee is a Director of the Company (i) comply with the provisions of
this Agreement and all policies and guidelines of the Board, any committees thereof or the Company applicable to Board members and (ii) to keep confidential all Company confidential information consistent with Board practices and applicable
policies, laws, rules and regulations and to not publicly disclose discussions and matters considered in meetings of the Board and Board committees. Each Lazarus Nominee acknowledges that his or her obligations under this Agreement are in
addition to the fiduciary and common law duties of any director of a Delaware corporation. 
  

	Section 2.	Company Obligations. 

 (a) Notwithstanding anything herein to the contrary, the
Company shall not be obligated to appoint any Lazarus Nominee to serve on the Board or cause to be nominated for election to the Board or recommend to the stockholders the election of any Lazarus Nominee: (i) who fails to submit to the Company
on a timely basis such questionnaires as the Company may reasonably require of its directors generally and such other information as the Company may reasonably request in connection with the preparation of its filings under the Securities Laws; or
(ii) if the Board or the Nominating Committee (if any) determines in good faith, after consultation with outside legal counsel, that (A) such action would constitute a breach of its fiduciary duties or applicable law or violate the
Company’s Certificate of Incorporation or By-Laws; or (B) such Lazarus Nominee would not be qualified under any applicable law, rule or regulation (including the rules of the Nasdaq Stock Market) to serve as a Director of the Company;
provided, however, that upon the occurrence of either (i) or (ii) above, the Company shall promptly notify the Lazarus Group of the occurrence of such event and permit the Lazarus Group to

  
 - 2 - 

 
provide an alternate nominee sufficiently in advance of any Board action, the meetings of the stockholders called or written action of stockholders with respect to such election of nominees and
the Company shall use commercially reasonable efforts to perform its obligations under this Agreement with respect to such alternate nominee (provided that if the Company provides at least 45 days advance notice of the occurrence of any such
event, such alternative nominee must be designated by the Lazarus Group not less than 30 days in advance of any Board action, notice of meeting of the stockholders or written action of stockholders with respect to such election of nominees), and in
no event shall the Company be obligated to postpone, reschedule or delay any scheduled meeting of the stockholders with respect to such election of nominees. 

(b) If at any time during the Designation Period a Board vacancy occurs solely because of the death, disability, disqualification, resignation
or removal of the Lazarus Nominee, then the Board, or any committee thereof, shall not fill such vacancy until the earliest to occur of: (i) the Lazarus Group’s designation of a successor nominee (which successor nominee shall be
designated in accordance with Section 1(c) and subject to the terms of Section 2(a)) and the Board’s appointment of such successor nominee to fill the vacancy; (ii) the Lazarus Group’s failure to designate a
successor nominee within 20 Business Days after receiving notification of the vacancy from the Company; or (iii) the Lazarus Group’s specifically waiving in writing its rights under this Section 2(b). For the purposes of
clarity, the Company shall have the right to fill any Board vacancy which may occur due to any reason other than the death, disability, disqualification, resignation or removal of the Lazarus Nominee in accordance with the terms of the
Company’s By-Laws and Certification of Incorporation. 
  

	Section 3.	Term and Termination. 

 Notwithstanding anything to the contrary contained herein,
upon the occurrence of a Termination Event, this Agreement shall be automatically terminated and of no further force and effect, and no party hereto shall have any surviving obligations, rights, or duties hereunder after such termination, other than
as may applicable to either party pursuant to Sections 1(g) and 1(h). Within three Business Days after the occurrence of a Termination Event (i) that results from a Transfer of Common Stock by any member of the Lazarus Group, the Lazarus
Group shall notify the Company of such event and (ii) that results from any other event or occurrence, the Company shall notify the Lazarus Group of such event (in each case, a “Termination Notice”). 

 

	Section 4.	Confidentiality. 

 The Company hereby agrees that: (i) the Lazarus
Nominee is permitted to and may provide confidential information to certain specified persons subject to and solely in accordance with the terms of the confidentiality agreement in the form attached hereto as Exhibit A (the
“Confidentiality Agreement”) (which the Lazarus Group shall execute and deliver to the Company simultaneously with the Lazarus Group’s execution and delivery of this Agreement) and (ii) the Company shall execute and
deliver the Confidentiality Agreement to the Lazarus Group substantially contemporaneously with execution and delivery thereof by the other signatories thereto. The Lazarus Group shall cause the Lazarus Nominee to execute such Confidentiality
Agreement as a condition of such Person being appointed to the Board. 
  

	Section 5.	Representations and Warranties.  

 (a) Each of the parties represents and
warrants to the other party that: (i) such party has all requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder; (ii) this Agreement has been duly and validly authorized, executed and
delivered by it and is a valid and binding obligation of such party, enforceable against such party in accordance with its terms; (iii) this Agreement will not result in a violation of any terms or conditions of any agreements to which

  
 - 3 - 

 
such person is a party or by which such party may otherwise be bound or of any law, rule, license, regulation, judgment, order or decree governing or affecting such party; and (iv) there is
currently no pending or outstanding litigation between the Lazarus Group and the Company or affiliates thereof concerning requests or demands by the Lazarus Group pursuant to Section 220 of the Delaware General Corporation Law or
otherwise. 
 (b) Each member of the Lazarus Group represents and warrants to the Company (i) that, as of the date of this
Agreement, the Lazarus Group beneficially owns such number of shares of Common Stock as is set forth in that certain Amendment to Schedule 13D filed by the Lazarus Group on September 4, 2014, and that neither the Lazarus Group, nor any
Affiliate thereof, beneficially owns any shares of Common Stock other than as a member of the Lazarus Group, and (ii) that it has no agreements, arrangements or understandings (written or oral) with respect to any shares of Common
Stock (including voting arrangements) other than this Agreement and the 2012 Board Agreement. 
  

	Section 6.	Definitions. 

 “Affiliate” means, with respect to any
Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person. 

“Agreement” has the meaning set forth in the preamble. 

“Beneficially Own” has the meaning ascribed to it in Rule 13d-3 and 13d-5 (or successor rules then in effect)
promulgated under Exchange Act. 
 “Business Day” means any day that is not a Saturday, Sunday, legal holiday or
other day on which commercial banks in New York, New York are authorized or required by applicable law to close. 

“By-Laws” means the Company’s By-Laws, as in effect on the date hereof, as the same may be amended from time to
time. 
 “Certificate of Incorporation” means the Company’s Certificate of Incorporation, as in effect on the
date hereof, as the same may be amended from time to time. 
 “Common Stock” means the common stock, par value
$0.001 per share, of the Company. 
 “Company” has the meaning set forth in the preamble. 

“Designation Period” means the period commencing on the Effective Date and expiring on the first to occur of a
Termination Event or the third anniversary of the Effective Date. 
 “Director” means a duly elected member of the
Board. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“Independent Director” means a Director that is an “independent director” as such term is defined from time
to time in the Nasdaq Stock Market’s listing standards (or the principal national securities exchange on which Common Stock is then traded) and is not an “affiliate” or an “associate” (as such terms are defined in Rule 12b-2
of the Exchange Act) or any member of the “immediate family” (as such term is defined in Rule 16a-1 of the Exchange Act) of a director or executive officer of the Company or the Lazarus Group and shall not have (or have had during the past
three years) any employment arrangement or other material commercial arrangement with any such person. For the avoidance of doubt, 

  
 - 4 - 

 
ownership of a 5% or less limited partnership interest in any fund managed by the Lazarus Group shall not be considered to constitute a material commercial arrangement. 

“Outstanding Equity” means, at any time, the issued and outstanding Common Stock of the Company (assuming (i) the
conversion of all outstanding shares of convertible preferred stock and (ii) exercise of all common stock purchase warrants then held by the Lazarus Group). 

“Person” means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock
company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof. 

“Securities Act” means the Securities Act of 1933, as amended from time to time. 

“Securities Laws” means the Securities Act and the Exchange Act, and the rules promulgated thereunder. 

“Termination Event” means the first to occur of (i) the date on which the Lazarus Group, together with the
Lazarus Affiliates, ceases to Beneficially Own at least 20.0% of the Outstanding Equity, whether as a result of dilution, Transfer or otherwise; (ii) the expiration of the Designation Period; or (iii) the expiration of any time period
within which the Lazarus Group may designate a successor nominee in accordance with Section 2(b) of this Agreement without such designation having been timely made. 

“Transfer” means any sale, transfer, assignment or other disposition of (whether with or without consideration and
whether voluntary or involuntary or by operation of law) of Common Stock or securities that may be exercisable or convertible into shares of Common Stock. 
  

	Section 7.	Provisions of General Applicability. 

 (a) Notices. Any notice provided for
in this Agreement shall be in writing and shall be deemed validly given, made or served, if (i) given by telecopy or email, when such telecopy or email is transmitted to the telecopy number set forth below or sent to the email address
set forth below and the appropriate confirmation is received or (ii) if given by any other means, when actually received during normal business hours at the address specified in this subsection. For the purpose of notices hereunder, it is
agreed that notices to be delivered to the Lazarus Nominee may be addressed and delivered to the Lazarus Group. 
  

					
	The Company’s address is:	  	Authentidate Holding Corp.
		  	300 Connell Drive, 5th Floor
		  	Berkeley Heights, NJ 07922
		  	Attention:	  	O’Connell Benjamin, President
		  	Facsimile:	  	(908) 673-9921
		  	Email:	  	obenjamin@authentidate.com
		
	with a copy to (which shall not constitute notice):	  	Becker & Poliakoff, LLP
		  	45 Broadway, 8th Floor
		  	New York, NY 10006
		  	Attention:	  	Michael A. Goldstein, Esq.
		  	Facsimile:	  	(212) 557-0295
		  	Email:	  	mgoldstein@bplegal.com

  
 - 5 - 

					
	The Lazarus Group’s address is:	  	Lazarus Investment Partners, LLLP
		  	3200 Cherry Creek South Drive, Suite 670
		  	Denver, CO 80209
		  	Attention:	  	Mr. Justin Borus
		  	Facsimile:	  	(303) 309-2675
		  	Email:	  	jborus@lazarusip.com
		
	with a copy to (which shall not constitute notice):	  	Lazarus Investment Partners, LLLP
		  	3200 Cherry Creek South Drive, Suite 670
		  	Denver, CO 80209
		  	Attention:	  	Adam Averbach, Esq.
		  	Facsimile:	  	(303) 309-2675
		  	Email:	  	aaverbach@lazarusip.com

 (b) Adjustments. If, and as often as, there are any changes in the Common Stock by way of stock split,
stock dividend, combination or reclassification, or through merger, consolidation, reorganization, recapitalization or sale, or by any other means, appropriate adjustment shall be made in the provisions of this Agreement, as may be required, so that
the rights, privileges, duties and obligations hereunder shall continue as so changed. 
 (c) Governing Law. All issues and questions
concerning the construction, validity, interpretation and enforceability of this Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules
or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. 

(d) Mutual Waiver of Jury Trial. The parties hereto hereby irrevocably waive any and all rights to trial by jury in any legal
proceeding arising out of or related to this Agreement. Any action or proceeding whatsoever between the parties hereto relating to this Agreement shall be tried in a court of competent jurisdiction by a judge sitting without a jury. 

(e) Remedies. The Company and the Lazarus Group shall be entitled to enforce their rights under this Agreement specifically, to recover
damages by reason of any breach of any provision of this Agreement and to exercise all other rights existing in their favor. The parties hereto agree and acknowledge that a breach of this Agreement would cause irreparable harm and money damages
would not be an adequate remedy for any such breach and that, in addition to other rights and remedies hereunder, the Company and the Lazarus Group shall be entitled to seek specific performance and/or injunctive or other equitable relief (without
posting a bond or other security) from any court of law or equity of competent jurisdiction in order to enforce or prevent any violation of the provisions of this Agreement. 

(f) Assignment; Benefit of Parties. No party may assign this Agreement or any of its rights or obligations hereunder without the
written consent of the other party. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns for the uses and purposes set forth and referred to herein. Nothing
in this Agreement, express or implied, is intended or shall be construed to confer upon, or give to, any person or entity other than the parties hereto and their respective successors and assigns, any remedy or claim under or by reason of this
Agreement or any terms, covenants or conditions hereof, and all of the terms, covenants, conditions, promises and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their respective
successors and assigns. 

  
 - 6 - 

 (g) Further Assurances. Each of the parties hereby agrees that it will hereafter execute
and deliver any further document, agreement, instruments of assignment, transfer or conveyance as may be necessary or desirable to effectuate the purposes hereof. 

(h) Counterparts. This Agreement may be executed in one or more counterparts, and may be delivered by means of facsimile or electronic
transmission in portable document format, each of which shall be deemed to be an original and shall be binding upon the party who executed the same, but all of such counterparts shall constitute the same agreement. 

(i) Complete Agreement; Inconsistent Agreements. This Agreement and the Confidentiality Agreement represent the complete agreement
between the parties hereto as to all matters covered hereby, and supersede any prior agreements or understandings between the parties. Notwithstanding the foregoing, however, this Agreement is independent of the Board Nomination and Observer
Agreement between the Company and the Lazarus Investment Partners, LLLP dated as of September 25, 2012, and as amended to date (the “2012 Board Agreement”) and nothing herein shall serve to amend or terminate either
parties’ obligations or rights arising under such 2012 Board Agreement. 
 (j) Severability. In the event any one or more of the
provisions contained in this Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby (it
being understood that the invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect the validity of such provision in any other jurisdiction). The parties shall endeavor in good-faith negotiations to replace
the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions. 

(k) Amendment and Waiver. Except as otherwise provided herein, no modification, amendment or waiver of any provision of this Agreement
shall be effective against the Company or the Lazarus Group unless such modification is approved in writing, in the case of an amendment, by the Company and the Lazarus Group, and in the case of a waiver, by each party against whom the waiver is to
be effective. The failure of any party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions and shall not affect the right of such party thereafter to enforce each and every provision of this
Agreement in accordance with its terms. 
 (l) No Strict Construction. The language used in this Agreement shall be deemed to be the
language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party. 

[SIGNATURE PAGE FOLLOWS] 

  
 - 7 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement, or caused the same to
be executed by its duly authorized representative, as of the day and year first above written. 
  

			
	THE COMPANY:
	
	AUTHENTIDATE HOLDING CORP.
		
	By:	 	 /s/ Charles C. Lucas

	Name:	 	 Charles C. Lucas III

	Title:	 	 Chairman of the Board

	
	THE LAZARUS GROUP:
	
	MR. JUSTIN B. BORUS
		
	By:	 	 /s/ Justin B. Borus

	Name:	 	 Justin B. Borus

	
	LAZARUS INVESTMENT PARTNERS LLLP
		
	By:	 	 Lazarus Management Company LLC

		 	 its General Partner

	By:	 	 /s/ Justin B. Borus

	Name:	 	 Justin B. Borus

	Title:	 	 Managing Member

	
	LAZARUS MANAGEMENT COMPANY LLC
		
	By:	 	 /s/ Justin B. Borus

	Name:	 	 Justin B. Borus

	Title:	 	 Managing Member

	
	THE LAZARUS NOMINEE:
	(with respect to the obligations set forth in Section 1(h) of the Board Nomination Agreement)
		
	By:	 	 /s/ Marc A. Horowitz

	Name:	 	 Marc A. Horowitz

 Signature Page to Board Nomination Agreement 

  
 - 8 - 

 SCHEDULE A 

Mr. Justin B. Borus 
 Lazarus Investment Partners LLLP

 Lazarus Management Company LLC 

  
 - 9 - 

 CONFIDENTIALITY AGREEMENT 

AUTHENTIDATE HOLDING CORP. 
 December 10, 2014 

 

	To:	Each of the persons or entities listed on Schedule A hereto (the “Group” or “you”) 

Ladies and Gentlemen: 
 This letter agreement
shall become effective upon the appointment of any Lazarus Nominee to the Board of Directors (the “Board”) of Authentidate Holding Corp. (the “Company”) pursuant to that certain Board Nomination Agreement, dated as
of December 10, 2014, among the Company and the Lazarus Group (the “Nomination Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Nomination Agreement. The
Company understands and agrees that, subject to the terms of, and in accordance with, this letter agreement, the Lazarus Nominee may, if and to the extent he or she desires to do so, disclose information he or she obtains while serving as a member
of the Board to you and your Representatives (as hereinafter defined), and may discuss such information with any and all such persons, subject to the terms and conditions of this agreement. As a result, you may receive certain non-public
information regarding the Company. You acknowledge that this information is proprietary to the Company and may include trade secrets or other business information the disclosure of which could harm the Company. In consideration for, and as
a condition of, the information being furnished to you and, subject to the restrictions in paragraph 2, the persons set forth on Schedule B hereto (collectively, the “Representatives”), you agree to treat any and all
information concerning or relating to the Company or any of its subsidiaries or affiliates that is furnished to you or your Representatives (regardless of the manner in which it is furnished, including in written or electronic format or orally,
gathered by visual inspection or otherwise) by either (i) any Lazarus Nominee, (ii) the individual nominated by Lazarus Investment Partners LLLP and elected to the Board of the Company in accordance with the terms of the Board Nomination
and Observer Agreement between the Company and Lazarus Investment Partners LLLP, dated as of September 25, 2012 (such person being the “Prior Lazarus Nominee”), or (iii) by or on behalf of the Company, together with any
notes, analyses, reports, models, compilations, studies, interpretations, documents, records or extracts thereof containing, referring, relating to, based upon or derived from such information, in whole or in part (collectively, “Evaluation
Material”), in accordance with the provisions of this letter agreement, and to take or abstain from taking the other actions hereinafter set forth. 

1. The term “Evaluation Material” does not include information that (i) is or has become generally available to the public
other than as a result of a direct or indirect disclosure by you or your Representatives in violation of this letter agreement or any other obligation of confidentiality, (ii) was within your or any of your Representatives’ possession on a
non-confidential basis prior to its being furnished to you by any Lazarus Nominee (including the Prior Lazarus Nominee), or by or on behalf of the Company or its agents, representatives, attorneys, advisors, directors, officers or employees
(collectively, the “Company Representatives”) or (iii) is received from a source other than any Lazarus Nominee, the Prior Lazarus Nominee, the Company or any of the Company Representatives; provided, that in the case of
(ii) or (iii) above, the source of such information was not believed by you, after reasonable inquiry of the disclosing person, to be bound by a confidentiality agreement with or other contractual, legal or fiduciary obligation of
confidentiality to the Company or any other person with respect to such information at the time the information was disclosed to you.

2. You and your Representatives will, and you will cause your Representatives to, (a) keep the Evaluation Material strictly
confidential and (b) not disclose any of the Evaluation Material in any 

  
 - 1 - 

 
manner whatsoever without the prior written consent of the Company; provided, however, that you may privately disclose any of such information: (A) to your Representatives
(i) who need to know such information for the sole purpose of advising you on your investment in the Company and (ii) who are informed by you of the confidential nature of such information; provided, further, that you will be
responsible for any violation of this letter agreement by your Representatives as if they were parties hereto; and (B) to the Company and the Company Representatives. It is understood and agreed that no Lazarus Nominee (including the Prior
Lazarus Nominee) shall disclose to you or your Representatives any Legal Advice (as defined below) that may be included in the Evaluation Material with respect to which such disclosure would constitute waiver of the Company’s attorney client
privilege or attorney work product privilege; provided, however, that a Lazarus Nominee may provide such disclosure of Legal Advice if he or she shall not have taken any action, or failed to take any action, that has the purpose or
effect of waiving attorney-client privilege or attorney work product privilege with respect to any portion of such Legal Advice and if reputable outside legal counsel provides the Company with a written opinion that such disclosure will not waive
the Company’s attorney client privilege or attorney work product privilege with respect to such Legal Advice. “Legal Advice” as used herein shall be solely and exclusively limited to the advice provided by legal counsel
and shall not include factual information or the formulation or analysis of business strategy that is not protected by the attorney-client or attorney work product privilege.

3. In the event that you or any of your Representatives are required by applicable subpoena, legal process or other legal requirement to
disclose any of the Evaluation Material, you will promptly notify (except where such notice would be legally prohibited) the Company in writing by email or facsimile and overnight courier so that the Company may seek a protective order or other
appropriate remedy (and if the Company seeks such an order, you will provide such cooperation as the Company shall reasonably request), at its cost and expense. Nothing herein shall be deemed to prevent you or your Representatives, as the case
may be, from honoring a subpoena, legal process or other legal requirement that requires discovery, disclosure or production of the Evaluation Material if (a) you produce or disclose only that portion of the Evaluation Material which your
outside legal counsel advises you is legally required to be so produced or disclosed and you inform the recipient of such Evaluation Material of the existence of this letter agreement and the confidential nature of such Evaluation Material; or
(b) the Company consents in writing to having the Evaluation Material produced or disclosed pursuant to the subpoena, legal process or other legal requirement. In no event will you or any of your Representatives oppose action by the
Company to obtain a protective order or other relief to prevent the disclosure of the Evaluation Material or to obtain reliable assurance that confidential treatment will be afforded the Evaluation Material. For the avoidance of doubt, it is
understood that there shall be no “legal requirement” requiring you to disclose any Evaluation Material solely by virtue of the fact that, absent such disclosure, you would be prohibited from purchasing, selling, or engaging in derivative
or other voluntary transactions with respect to the Common Stock of the Company or otherwise proposing or making an offer to do any of the foregoing, or you would be unable to file any proxy materials in compliance with Section 14(a) of the
Exchange Act or the rules promulgated thereunder. 
 4. You acknowledge that (a) none of the Company or any of the Company
Representatives makes any representation or warranty, express or implied, as to the accuracy or completeness of any Evaluation Material, and (b) none of the Company or any of the Company Representatives shall have any liability to you or to any
of your Representatives relating to or resulting from the use of the Evaluation Material or any errors therein or omissions therefrom. You and your Representatives (or anyone acting on your or their behalf) shall not directly or indirectly
initiate contact or communication with any executive or employee of the Company other than the Chief Executive Officer or Chief Financial Officer of the Company, and/or such other persons approved in writing by the foregoing or the Board concerning
Evaluation Material, or to seek any information in connection therewith from any such person other than 

  
 - 2 - 

 
the foregoing, without the prior consent of the Company; provided, however, the restriction in this sentence shall not in any way apply to any Lazarus Nominee or other Board members. 

5. All Evaluation Material shall remain the property of the Company. Neither you nor any of your Representatives shall by virtue of
any disclosure of and/or your use of any Evaluation Material acquire any rights with respect thereto, all of which rights (including all intellectual property rights) shall remain exclusively with the Company. At any time after the date on
which no Lazarus Nominee is a director of the Company, upon the request of the Company for any reason, you will promptly return to the Company or destroy all hard copies of the Evaluation Material and use commercially reasonable efforts to
permanently erase or delete all electronic copies of the Evaluation Material in your or any of your Representatives’ possession or control (and, upon the request of the Company, shall certify to the Company that such Evaluation Material has
been erased or deleted, as the case may be). Notwithstanding the return or erasure or deletion of Evaluation Material, you and your Representatives will continue to be bound by the obligations contained herein. 

6. You acknowledge, and will advise your Representatives, that the Evaluation Material may constitute material non-public information
under applicable federal and state securities laws, and that you shall not, and you shall use your commercially reasonable efforts to ensure that your Representatives, do not, trade or engage in any derivative or other transaction, on the basis of
such information in violation of such laws. 
 7. You hereby represent and warrant to the Company that (i) you have all requisite
company power and authority to execute and deliver this letter agreement and to perform your obligations hereunder, (ii) this letter agreement has been duly authorized, executed and delivered by you, and is a valid and binding obligation,
enforceable against you in accordance with its terms, (iii) this letter agreement will not result in a violation of any terms or conditions of any agreements to which you are a party or by which you may otherwise be bound or of any law, rule,
license, regulation, judgment, order or decree governing or affecting you, and (iv) your entry into this letter agreement does not require approval by any owners or holders of any equity or other interest in you (except as has already been
obtained). 
 8. Any waiver by the Company of a breach of any provision of this letter agreement shall not operate as or be construed
to be a waiver of any other breach of such provision or of any breach of any other provision of this letter agreement. The failure of the Company to insist upon strict adherence to any term of this letter agreement on one or more occasions
shall not be considered a waiver or deprive the Company of the right thereafter to insist upon strict adherence to that term or any other term of this letter agreement. 

9. You acknowledge and agree that the value of the Evaluation Material to the Company is unique and substantial, but may be impractical
or difficult to assess in monetary terms. You further acknowledge and agree that in the event of an actual or threatened violation of this letter agreement, immediate and irreparable harm or injury would be caused for which money damages would
not be an adequate remedy. Accordingly, you acknowledge and agree that, in addition to any and all other remedies which may be available to the Company at law or equity, the Company shall be entitled to an injunction or injunctions to prevent
breaches of this letter agreement and to enforce specifically the terms and provisions of this letter agreement exclusively in the Court of Chancery or other federal or state courts of the State of Delaware. In the event that any action shall
be brought in equity to enforce the provisions of this letter agreement, you shall not allege, and you hereby waive the defense, that there is an adequate remedy at law. 

10. Each of the parties hereto (a) consents to submit itself to the personal jurisdiction of the Court of Chancery or other federal
or state courts of the State of Delaware in the event any dispute arises 

  
 - 3 - 

 
out of this letter agreement or the transactions contemplated by this letter agreement, (b) agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other
request for leave from any such court, (c) agrees that it shall not bring any action relating to this letter agreement or the transactions contemplated by this letter agreement in any court other than the Court of Chancery or other federal or
state courts of the State of Delaware, and each of the parties irrevocably waives the right to trial by jury, (d) agrees to waive any bonding requirement under any applicable law, in the case any other party seeks to enforce the terms by way of
equitable relief, and (e) irrevocably consents to service of process by a reputable overnight delivery service, signature requested, to the address of such party’s principal place of business or as otherwise provided by applicable
law. THIS LETTER AGREEMENT SHALL BE GOVERNED IN ALL RESPECTS, INCLUDING VALIDITY, INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE OF DELAWARE APPLICABLE TO CONTRACTS EXECUTED AND TO BE PERFORMED WHOLLY WITHIN SUCH STATE WITHOUT GIVING
EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE. 
 11. This letter agreement and the Nomination Agreement contain the entire
understanding of the parties with respect to the subject matter hereof and thereof and supersedes all prior or contemporaneous agreements or understandings, whether written or oral. This letter agreement may be amended only by an agreement in
writing executed by the parties hereto.
 12. All notices, consents, requests, instructions, approvals and other communications
provided for herein and all legal process in regard hereto shall be in writing and shall be deemed validly given, made or served, if (a) given by telecopy or email, when such telecopy is transmitted to the telecopy number set forth below or
such email is sent to the email address set forth below and the appropriate confirmation is received or (b) if given by any other means, when actually received during normal business hours at the address specified in this subsection. For the
purpose of notices hereunder, it is agreed that notices to be delivered to the Lazarus Nominee may be addressed and delivered to the Lazarus Group. 
  

					
	If to the Company:	  	Authentidate Holding Corp.
		  	300 Connell Drive, 5th Floor
		  	Berkeley Heights, NJ 07922
		  	Attention:	  	O’Connell Benjamin, President
		  	Facsimile:	  	(908) 673-9921
		  	Email:	  	obenjamin@authentidate.com
		
	with copies to (which shall not constitute notice):	  	Becker & Poliakoff, LLP
		  	45 Broadway, 8th Floor
		  	New York, NY 10006
		  	Attention:	  	Michael A. Goldstein, Esq.
		  	Facsimile:	  	(212) 557-0295
		  	Email:	  	mgoldstein@bplegal.com
		
	The Lazarus Group’s address is:	  	Lazarus Investment Partners LLLP
		  	3200 Cherry Creek South Drive, Suite 670
		  	Denver, CO 80209
		  	Attention:	  	Mr. Justin Borus
		  	Facsimile:	  	(303) 309-2675
		  	Email:	  	jborus@lazarusip.com

  
 - 4 - 

					
	with copies to (which shall not constitute notice):	  	Lazarus Investment Partners LLLP
		  	3200 Cherry Creek South Drive, Suite 670
		  	Denver, CO 80209
		  	Attention:	  	Adam Averbach, Esq.
		  	Facsimile:	  	(303) 309-2675
		  	Email:	  	aaverbach@lazarusip.com

 13. If at any time subsequent to the date hereof, any provision of this letter agreement shall be held by
any court of competent jurisdiction to be illegal, void or unenforceable, such provision shall be of no force and effect, but the illegality or unenforceability of such provision shall have no effect upon the legality or enforceability of any other
provision of this letter agreement. 
 14. This letter agreement may be executed (including by facsimile or PDF) in two or more
counterparts which together shall constitute a single agreement. 
 15. This letter agreement and the rights and obligations herein may
not be assigned or otherwise transferred, in whole or in part, by you without the express written consent of the Company. This letter agreement, however, shall be binding on successors of the parties hereto. 

16. The Lazarus Group shall cause any Lazarus Nominee (including any Replacement) appointed to the Board pursuant to the Nomination
Agreement to execute a copy of this letter agreement.
 17. This letter agreement shall expire two (2) years from the date on
which any Lazarus Nominee ceases to be a director of the Company; except that you shall maintain in accordance with the confidentiality obligations set forth herein any Evaluation Material constituting trade secrets for such longer time as such
information constitutes a trade secret of the Company as defined under 18 U.S.C. § 1839(3). 
 18. No licenses or rights under any
patent, copyright, trademark, or trade secret are granted or are to be implied by this letter agreement. 
 19. Each of the parties
hereto acknowledges that it has been represented by counsel of its choice throughout all negotiations that have preceded the execution of this letter agreement, and that it has executed the same with the advice of said counsel. Each party and its
counsel cooperated and participated in the drafting and preparation of this agreement and the documents referred to herein, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties
and may not be construed against any party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this agreement against any party that drafted or prepared
it is of no application and is hereby expressly waived by each of the parties hereto, and any controversy over interpretations of this agreement shall be decided without regards to events of drafting or preparation. The term “including”
shall in all instances be deemed to mean “including without limitation.” 
 [Signature Page Follows] 

  
 - 5 - 

 Please confirm your agreement with the foregoing by signing and returning one copy of this letter
agreement to the undersigned, whereupon this letter agreement shall become a binding agreement between you and the Company. 
  

			
	Very truly yours,
	
	AUTHENTIDATE HOLDING CORP.
		
	By:	 	 /s/ Charles C. Lucas

	Name:	 	 Charles C. Lucas III

	Title:	 	 Chairman of the Board

 Accepted and agreed as of the date first written above: 

THE LAZARUS GROUP: 
  

			
	MR. JUSTIN B. BORUS
		
	By:	 	 /s/ Justin B. Borus

	Name:	 	 Justin B. Borus

	
	LAZARUS INVESTMENT PARTNERS LLLP
		
	By:	 	 Lazarus Management Company LLC

		 	 its General Partner

	By:	 	 /s/ Justin B. Borus

	Name:	 	 Justin B. Borus

	Title:	 	 Managing Member

	
	LAZARUS MANAGEMENT COMPANY LLC
		
	By:	 	 /s/ Justin B. Borus

	Name:	 	 Justin B. Borus

	Title:	 	 Managing Member

	
	THE LAZARUS NOMINEE:
		
	By:	 	 /s/ Marc A. Horowitz

	Name:	 	 Marc A. Horowitz

 [Signature Page to the Confidentiality Agreement between 

Authentidate Holding Corp. and Lazarus Group] 

  
 - 6 - 

 SCHEDULE A 

Mr. Justin B. Borus 
 Lazarus Investment Partners LLLP

 Lazarus Management Company LLC 

  
 - 7 - 

 SCHEDULE B 

Mr. Justin B. Borus 

  
 - 8 -exhibit1056

Exhibit 10.56

SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of November 26, 2014, is by and among Alimera Sciences, Inc. (the “Company”) and Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Private Design Fund III, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Special Situations Fund International Master Fund, L.P. (collectively the “Investors”).

RECITALS
WHEREAS, the Company has filed with the Securities and Exchange Commission (the “Commission”) the Registration Statement (as defined below) relating to the offer and sale from time to time of the Company’s securities, including shares of its common stock, par value $0.01 per share (the “Common Stock”) and shares of its preferred stock, par value $0.01 per share (“Preferred Stock”);
WHEREAS, the Board of Directors of the Company has authorized the creation of a new series of Preferred Stock denominated as Series B Convertible Preferred Stock (“Series B Preferred Stock”);
WHEREAS, the Company is offering for sale shares of Series B Preferred Stock and the Conversion Shares (as defined below) pursuant to the Registration Statement; 
WHEREAS, the Investors desire to purchase from the Company shares of Series B Preferred Stock on the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the foregoing recitals (which are deemed to be a part of this Agreement), mutual covenants, representations, warranties and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1.Definitions.  As used herein, the following terms have the meanings indicated:
“Aggregate Purchase Price” shall have the meaning set forth in Section 2(a) hereof. 
“Business Day” means any day other than Saturday, Sunday or a day on which banks in the City of New York are authorized or required to be closed.
“Certificate of Designation” means the Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock, in the form attached hereto as Exhibit A.
“Common Stock Equivalents” shall mean any securities of the Company which would entitle the holder thereof to acquire, directly or indirectly, at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other      

instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock or other securities that entitle the holder to receive, directly or indirectly, Common Stock.
“Conversion Shares” shall mean shares of Common Stock issuable upon conversion of Series B Preferred Stock.
“Investor Shares” means 8,416.252 shares of Series B Preferred Stock.
“knowledge” means with respect to any statement made to the Company’s knowledge, that statement is based upon the actual knowledge of the Company or its Chief Executive Officer or Chief Operating Officer and Chief Financial Officer.
“Loss” shall have the meaning set forth in Section 5 hereof.
“Material Adverse Effect” shall mean a material adverse effect on (a) the business, operations, financial condition or assets of the Company or its subsidiaries taken as a whole, (b) the validity or enforceability of any provision of this Agreement, or (c) the rights and remedies of the Investors under this Agreement.
“Person” shall mean any individual, partnership, limited liability company, joint venture, firm, corporation, association, trust or other enterprise or any government or political subdivision or any agency, department or instrumentality thereof.
“Principal Trading Market” shall mean whichever of the New York Stock Exchange, the NYSE Alternext (formerly the American Stock Exchange), the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or the OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question.
“Prospectus” shall have the meaning set forth in Section 4(b)(7) hereof.
“Prospectus Supplement” shall mean the prospectus supplement to be filed with the Commission regarding the Investor Shares and the Conversion Shares pursuant to Rule 424(b) promulgated under the Securities Act (“Rule 424(b)”) and deemed to be part of the Registration Statement at the time of effectiveness.
“Registration Statement” shall mean the registration statement on Form S‐3 (File No. 333-198044), including a prospectus, and including all amendments and supplements thereto (including the Prospectus Supplement), relating to the offer and sale of certain of the Company’s Common Stock, Preferred Stock, Debt Securities and Warrants, including the Investor Shares and the Conversion Shares.  References herein to the term “Registration Statement” as of any date shall mean such effective registration statement, as amended or supplemented to such date, including all information and documents incorporated by reference therein as of such date.
“Securities Act” shall mean the Securities Act of 1933, as amended.

    
2

2.    Purchase of Series B Preferred Stock.  
(a)    Subject and pursuant to the terms and conditions set forth in this Agreement, the Company agrees that it will issue and sell to the Investors, and the Investors agree that they will purchase from the Company, the number of Investor Shares set forth after their name on Schedule 1 attached hereto in the column headed “Number of Shares of Series B Preferred Stock to be Purchased by Investor Pursuant to Section 2(a)” at a purchase price of $6,030 for each Investor Share and an aggregate purchase price of $50,000,000 (the “Aggregate Purchase Price”).  The closing of the purchase and sale of the Investor Shares will take place not more than fifteen (15) Business Days following the date of this Agreement, or such other date or time as the parties may agree upon in writing (the “Closing”).    
(b)    At the Closing, the Investors shall be entitled to receive a subscription premium equal to 1.5% of the Aggregate Purchase Price which shall be payable by the issuance of additional Investor Shares as set forth on Schedule 1 hereto.
3.    Deliveries at Closing.
(a)    Deliveries by the Investor.  At the Closing, each Investor shall deliver to the Company the Aggregate Purchase Price set forth next to its name on Schedule 1 hereto by wire transfer of immediately available funds to a bank account designated in writing by the Company to the Investors, which funds will be delivered to the Company in consideration of the Investor Shares issued at the Closing. 
(b)    Deliveries by the Company.  At the Closing, the Company shall
(1)    deliver to each Investor stock certificates in a form, reasonably satisfactory to the Investors, registered in the name of such Investor evidencing the number of shares of Series B Preferred Stock issuable to such Investor; and
(2)    deliver evidence satisfactory to the Investors, that the Certificate of Designation has been filed with the Secretary of State of Delaware and has become effective on or prior to the Closing.
4.    Representations, Warranties, Covenants and Agreements.
(a)    Investor Representations, Warranties and Covenants.  Each Investor represents, warrants, covenants and agrees as follows as of the date hereof and as of the Closing:
(3)    Investor has received and reviewed copies of the Registration Statement and the Prospectus, including all documents and information incorporated by reference therein and amendments thereto, and understands that no Person has been authorized to give any information or to make any representations that were not contained in the Registration Statement and the Prospectus, and Investor has not relied on any such other information or representations in making a decision to acquire the Investor Shares.  Investor hereby consents to receiving delivery of the Registration Statement and the Prospectus, including all documents and information incorporated by reference therein and amendments thereto, by electronic mail or by                          

    
3

accessing the EDGAR database on the Commission’s website.  Investor understands that an investment in the Company involves a high degree of risk for the reasons, among others, set forth under the caption “Risk Factors” in the Prospectus.
(4)    Investor acknowledges that it has sole responsibility for its own due diligence investigation and its own investment decision, and that in connection with its investigation of the accuracy of the information contained or incorporated by reference in the Registration Statement and the Prospectus and its investment decision, Investor has not relied on any representation or information, as the case may be, not set forth in this Agreement, the Registration Statement or the Prospectus, or any Person affiliated with the Company or on the fact that any other Person has decided to purchase the Investor Shares.
(5)    The execution and delivery of this Agreement by Investor and the performance of this Agreement and the consummation by Investor of the transactions contemplated hereby have been duly authorized by all necessary corporate or partnership action of Investor, as applicable, and this Agreement, when duly executed and delivered by Investor, will constitute a valid and legally binding instrument, enforceable in accordance with its terms against Investor, except as enforcement hereof may be limited by the effect of any applicable bankruptcy, insolvency, reorganization or similar laws or court decisions affecting enforcement of creditors’ rights generally and except as enforcement hereof is subject to general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at law).
(b)    Company Representations, Warranties and Covenants.  The Company hereby represents, warrants, covenants and agrees as follows as of the date hereof and as of the Closing:
(1)    The Company has been duly incorporated and is validly existing as a corporation under the laws of the State of Delaware, with corporate power and authority to own its properties and conduct its business as described in the Prospectus, and has been duly qualified as a foreign corporation for the transaction of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except for such jurisdictions wherein the failure to be so qualified and in good standing would not individually or in the aggregate have a Material Adverse Effect.
(2)    Each subsidiary of the Company has been duly incorporated or organized and is validly existing in good standing (to the extent the concept of good standing exists in the subsidiary’s jurisdiction or incorporation or organization) under the laws of its jurisdiction of incorporation or organization, with power and authority to own its properties and conduct its business as described in the Prospectus, and has been duly qualified for the transaction of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except for such jurisdictions wherein the failure to be so qualified and in good standing would not individually or in the aggregate have a Material Adverse Effect.  Except as disclosed by the Company’s periodic reports filed with the Commission and except as required pursuant to this Agreement and as of the date of the most recent quarterly report filed by the Company, there are no outstanding (i) securities of the Company or any of the subsidiaries of the Company which are convertible into or exchangeable for shares of capital stock or voting securities of any subsidiary of the Company or (ii) options or other rights to 

    
4

acquire from the Company or any subsidiary of the Company, or other obligation of the Company or any subsidiary of the Company to issue, any capital stock, voting securities or securities convertible into or exchangeable for capital stock or voting securities of any subsidiary of the Company (collectively, the “Subsidiary Securities”).  There are no outstanding obligations of the Company or any subsidiary of the Company to repurchase, redeem or otherwise acquire any outstanding Subsidiary Securities.
(3)    The execution, delivery and performance of this Agreement by the Company and the consummation of the transactions contemplated hereby are within the corporate powers of the Company and have been duly authorized by all necessary corporate action on the part of the Company and this Agreement, when duly executed and delivered by the parties hereto, will constitute a valid and legally binding instrument of the Company enforceable in accordance with its terms, except as enforcement hereof may be limited by the effect of any applicable bankruptcy, insolvency, reorganization or similar laws or court decisions affecting enforcement of creditors’ rights generally and except as enforcement hereof is subject to general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at law).
(4)    The Investor Shares have been duly authorized by the Company, and when issued and delivered by the Company against payment therefor as contemplated by this Agreement will be validly issued, fully paid and nonassessable, and will conform to the description of the Series B Preferred Stock contained in the Prospectus.  The Investor Shares and the Conversion Shares will be issued in compliance with all federal and state securities laws.
(5)    The Company has reserved from its duly authorized capital stock a number of shares of Common Stock sufficient for issuance of all of the Conversion Shares. The Conversion Shares, when issued, will have been duly authorized and, when issued, delivered and paid for in accordance with the terms of the Certificate of Designation, will have been validly issued and will be fully paid and nonassessable. The Company shall, so long as any of the Series B Preferred Stock is outstanding, take all action necessary to reserve and keep available out of its authorized and unissued capital stock, solely for the purpose of effecting the conversion of the Series B Preferred Stock, the number of shares of Common Stock issuable upon such conversion (without taking into account any limitations on the conversion of the Series B Preferred Stock set in the Certificate of Designation).  
(6)    The execution and delivery of this Agreement do not, and the compliance by the Company with the terms hereof will not, (i) violate the Certificate of Incorporation (as amended to date) of the Company or the By‐Laws (as amended to date) of the Company, (ii) result in a breach or violation of any of the terms or provisions of, or constitute a material default under, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of their properties or assets are subject, or (iii) result in a violation of, or failure to be in compliance with, any applicable statute or any order, judgment, decree, rule or regulation of any court or governmental, regulatory or self-regulatory agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties or assets, except where such breach, violation, default or the failure to be in compliance would not individually or in the aggregate have a Material Adverse Effect or adversely affect the ability of the Company to issue and sell the Investor Shares; and no consent, 

    
5

approval, authorization, order, registration, filing or qualification of or with any such court or governmental, regulatory or self-regulatory agency or body is required for the valid authorization, execution, delivery and performance by the Company of this Agreement or the issuance of the Investor Shares, except for the filing of one or more Form 8-Ks, the filing of the Prospectus Supplement, the filing of the Certificate of Designation (which is required to be filed and effective prior to the Closing in accordance with Section 3(b)(2) hereof), the filing of a Notification of Listing of Additional Shares with The NASDAQ Stock Market LLC, and for such consents, approvals, authorizations, registrations, filings or qualifications as may be required under state securities or “blue sky” laws.
(7)    The Company meets the requirements for use of Form S-3 under the Securities Act. The Registration Statement, which covers the Investor Shares and the Conversion Shares, including a form of prospectus and such amendments or supplements to such Registration Statement as may have been required prior to the date of this Agreement, has been prepared by the Company under the provisions of the Securities Act, has been filed with the Commission, has become effective and filed with the Commission and incorporates by reference documents which the Company has filed in accordance with the provisions of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  The Company has prepared a Prospectus Supplement to the prospectus included in the Registration Statement referred to above, setting forth the terms of the offering and sale of the Investor Shares and additional information concerning the Company and its business and will promptly file the Prospectus Supplement with the Commission pursuant to Rule 424(b).  No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, or any part thereof, has been issued and served on the Company, and no proceedings for that purpose are pending or, to the knowledge of the Company, threatened by the Commission.  The form of prospectus included in the Registration Statement as of the date hereof, as amended or supplemented from time to time (including the Prospectus Supplement), is referred to herein as the “Prospectus.”  Any reference herein to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated (or deemed to be incorporated) by reference therein, and any reference herein to the terms “amend,” “amendment” or “supplement” with respect to the Registration Statement or Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein.  As of the close of business on November 26, 2014, at least a number of shares of Preferred Stock and Common Stock equal to the number of Investor Shares and Conversion Shares, respectively, were available for issuance pursuant to the Registration Statement, which permits the issuance of the Investor Shares and the Conversion Shares in the manner contemplated by this Agreement.
Each part of the Registration Statement, when such part became or becomes effective, and the Prospectus and any amendment or supplement thereto, on the date of filing thereof with the Commission and at the date hereof and the date of the Closing, did or will in all material respects comply with all applicable provisions of the Securities Act and the Exchange Act. Each part of the Registration Statement, when such part became or becomes effective, did not or will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading.  The Prospectus and any amendment or supplement thereto, on the date of filing thereof with the Commission, did not or will not contain any untrue statement of a material fact or omit to state a 

    
6

material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, and any statutes, regulations, contracts or other documents that are required to be described in the Registration Statement or Prospectus or to be filed as exhibits to the Registration Statement have been so described or filed.  
(8)    The consolidated financial statements and financial schedules of the Company included or incorporated by reference in the Registration Statement and the Prospectus have been prepared in conformity with generally accepted accounting principles (except, with respect to the unaudited consolidated financial statements, for the footnotes and subject to customary audit adjustments) applied on a consistent basis, are consistent in all material respects with the books and records of the Company, and accurately present in all material respects the consolidated financial position, results of operations and cash flow of the Company and its subsidiaries as of and for the periods covered thereby.
(9)    Neither the Company nor any of its subsidiaries has sustained since the respective dates of the latest audited financial statements included or incorporated by reference in the Registration Statement and Prospectus any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as disclosed in or contemplated by the Registration Statement and Prospectus; and, since the respective dates as of which information is given in the Registration Statement and Prospectus, other than as contemplated in this Agreement, there has not been any material change in the capital stock or long-term debt of the Company or any of its subsidiaries.
(10)    Other than as disclosed in the Prospectus, there are no legal, governmental or regulatory proceedings pending to which the Company or any of its subsidiaries is a party or of which any material property of the Company or any of its subsidiaries is the subject which, taking into account the likelihood of the outcome, the damages or other relief sought and other relevant factors, would individually or in the aggregate reasonably be expected to have a Material Adverse Effect or adversely affect the ability of the Company to issue and sell the Investor Shares, and no such proceedings are threatened in writing to the Company or, to the Company’s knowledge, have been contemplated by governmental or regulatory authorities or threatened by others.
(11)    The Company and each of its subsidiaries have title to all the real property, and owns all other properties and assets, reflected as owned in the financial statements included or incorporated by reference in the Registration Statement and the Prospectus, subject to no lien, mortgage, pledge, charge or encumbrance of any kind except those, if any, reflected in such financial statements or disclosed in the Company’s  filings with the Commission or exhibits thereto, or which are not material to the Company and its subsidiaries taken as a whole.  The Company and each of its subsidiaries hold their respective leased real and personal properties under valid and binding leases, except where the failure to do so would not reasonably be expected to individually or in the aggregate have a Material Adverse Effect.
(12)    The Company has filed all necessary federal and state income and franchise tax returns and has paid all taxes shown as due thereon or has filed all necessary extensions, 

    
7

and there is no tax deficiency that has been, or to the knowledge of the Company could reasonably be expected to be, asserted against the Company or any of its properties or assets that would in the aggregate or individually reasonably be expected to have a Material Adverse Affect.
(13)    There are no holders of securities of the Company having preemptive rights to purchase Common Stock.  There are no holders or beneficial owners of securities of the Company having rights to registration thereof whose securities have not been previously registered or who have not waived such rights with respect to the registration of the Company’s securities on the Registration Statement, except where the failure to obtain such waiver would not individually or in the aggregate reasonably be expected to have a Material Adverse Effect.
(14)    The issuance of the Investor Shares and the Conversion Shares will not obligate the Company to issue shares of Common Stock or other Common Stock Equivalents to any Person (other than the Investors), will not trigger any preemptive or other rights to subscribe for or purchase securities and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price or other right under any of such securities.  
(15)    The Company is not, and does not intend to conduct its business in a manner in which it would become, an “investment company” as defined in Section 3(a) of the Investment Company Act of 1940, as amended.
(16)    The Company is in compliance in all material respects with all listing and maintenance requirements of the Principal Trading Market.  The issuance and sale of the Investor Shares and the issuance of the Conversion Shares will, at the time of such issuance and sale, comply in all material respects with and will not contravene the rules and regulations of the Principal Trading Market.  The Conversion Shares, when issued, will be listed for trading on the Principal Trading Market.
5.    Indemnification.   
(a)    Subject to the limitations and other provisions of this Section 5, the Company covenants and agrees to indemnify, defend and hold harmless the Investors and their respective directors, officers, partners, managers, employees and agents (each, an “Investor Party”) from and against any and all Losses arising from claims by third parties resulting from, incurred in connection with or arising out of (but only to the extent of) (a) any breach of any representation, warranty or covenant of the Company contained herein, or (b) the failure of the Company to perform any of the agreements, covenants or obligations contained herein (other than if any such claim was a result of a breach by the Investor hereunder).  Subject to the limitations and other provisions of this Section 5, the Investor covenants and agrees to indemnify, defend and hold harmless the Company from and against (but only to the extent of) any and all Losses arising from claims by third parties resulting from, incurred in connection with or arising out of (but only to the extent of) (a) any breach of any representation or warranty of the Investor contained herein, or (b) the failure of the Investor to perform any of the agreements, covenants or obligations of the Investor contained herein.  The term “Loss” or any similar term shall mean any and all damages, deficiencies, costs, claims, fines, judgments, amounts paid in settlement, 

    
8

expenses of investigation, interest, penalties, taxes, assessments, out-of-pocket expenses (including reasonable attorneys’ and auditors’ fees and disbursements, witness fees and court costs) but specifically excluding consequential, special, punitive, multiple and other similar damages.  The party or parties being indemnified are referred to herein as the “Indemnitee” and the indemnifying party is referred to herein as the “Indemnitor.”
(b)    Indemnification Procedure.
(1)    Any party who receives notice of a potential claim that may, in the judgment of such party, result in a Loss shall use all reasonable efforts to provide the parties hereto notice thereof within fifteen (15) days of the filing or other written assertion of any such claim against the Indemnitee, provided that failure or delay or alleged delay in providing such notice shall not adversely affect such party’s right to indemnification hereunder, unless and then only to the extent that such failure or delay or alleged delay has resulted in actual prejudice to the Indemnitor, including, without limitation, by the expiration of a statute of limitations.  In the event that any party shall incur or suffer any Losses in respect of which indemnification may be sought by such party hereunder, the Indemnitee shall assert a claim for indemnification by written notice (a “Notice”) to the Indemnitor stating the nature and basis of such claim.  
(2)    In the case of third party claims for which indemnification is sought, the Indemnitor shall, if necessary, retain counsel reasonably satisfactory to the Indemnitee, and have the option (i) to conduct any proceedings or negotiations in connection therewith, (ii) to take all other steps to settle or defend any such claim (provided that the Indemnitor shall not settle any such claim without the consent of the Indemnitee which consent shall not be unreasonably withheld or delayed) and (iii) to employ counsel to contest any such claim or liability in the name of the Indemnitee or otherwise.  In any event, the Indemnitee shall be entitled to participate at its own expense and by its own counsel in any proceedings relating to any third party claim.  The Indemnitor shall, within fifteen (15) Business Days of receipt of the Notice, notify the Indemnitee of its intention to assume the defense of such claim.  If (i) the Indemnitor shall decline to assume the defense of any such claim, (ii) the Indemnitor shall fail to notify the Indemnitee within fifteen (15) Business Days after receipt of the Notice of the Indemnitor’s election to defend such claim or (iii) in the reasonable opinion of counsel for the Indemnitee, the representation by the same counsel of the Indemnitor and the Indemnitee would be inappropriate due to actual or potential material differing interests between such Indemnitee and any other party represented by such counsel in such proceeding, then in each such case the Indemnitor shall not have the right to direct the defense of such action on behalf of the Indemnitee and the Indemnitee shall, at the sole expense of the Indemnitor, defend against such claim; provided, that the Indemnitee may not settle such claim without the consent of the Indemnitor (which consent will not be unreasonably withheld or delayed).  In such event, the Indemnitor shall pay for only one separate legal counsel for the Indemnitees, and such legal counsel shall be selected by the Indemnitee.  The reasonable expenses of all proceedings, contests or lawsuits in respect of such claims shall be borne and paid by the Indemnitor if the Indemnitee is entitled to indemnification hereunder and the Indemnitor shall pay the Indemnitee, in immediately available funds, the amount of any Losses, within a reasonable time of the incurrence of such Losses.  Regardless of which party shall assume the defense or negotiation of the settlement of the claim, the parties agree to cooperate fully with one another in connection therewith.  Anything in this Section 5 to the contrary notwithstanding, the Indemnitor shall not, 

    
9

without the Indemnitee’s prior written consent, settle or compromise any claim or consent to entry of any judgment in respect thereof which imposes any future obligation on the Indemnitee or which does not include, as an unconditional term thereof, the giving by the claimant or plaintiff to the Indemnitee, a release from all liability in respect of such claim. 
(c)    No Waiver.  Nothing herein shall in any way limit a Party’s remedies in respect of a breach of any representation, warranty or covenant hereunder.
6.    Conditions.  
(a)    The obligation of each Investor to purchase and acquire the Investor Shares hereunder shall be subject to the conditions that:
(3)    All representations and warranties of the Company herein shall be true and correct in all material respects as of and on each of the date of this Agreement and the date of the Closing;
(4)    The Company shall have performed all of its obligations hereunder; including delivery of certificates for the Series B Preferred Stock;
(5)    The Prospectus Supplement shall have been filed with the Commission pursuant to Rule 424(b) within the applicable time period prescribed for such filing, no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission, and the Investor shall have received the Prospectus in accordance with the federal securities laws.
(b)    The obligation of the Company to sell the Investor Shares hereunder shall be subject to the conditions that:
(1)    All representations and warranties and other statements of the Investors herein shall be true and correct in all material respects as of and on each of the date of this Agreement and the date of the Closing; 
(2)    The Investors shall have performed all of their obligations hereunder.
7.    Covenants.
(a)    Fees and Costs.  The Company will reimburse the Investors for reasonable, documented expenses for attorneys, accountants and other professional advisors, and other out-of-pocket expenses incurred by Investors in connection with their due diligence, negotiation and documentation of the transactions contemplated up to an aggregate amount of $200,000.  
(b)    The Company shall, so long as any of the Investor Shares is outstanding, take all action necessary to reserve and keep available out of its authorized and unissued capital stock, solely for the purpose of effecting the conversion of the Investor Shares, the number of 

    
10

shares of Common Stock issuable upon such conversion (without taking into account any limitations on the conversion of the Series B Preferred Stock set forth in the Certificate of Designation), free and clear of all encumbrances and restrictions. The Company shall cause the Conversion Shares, when issued in accordance with the provisions of the Certificate of Designation, to be duly authorized, validly issued and fully paid and non-assessable.
8.    Miscellaneous.
(a)    Binding Agreement; Assignment.  This Agreement shall be binding upon, and shall inure solely to the benefit of, each of the parties hereto, and each of their respective heirs, executors, administrators, successors and assigns, and no other person other than Indemnitees shall acquire or have any right under or by virtue of this Agreement.  The Company may not assign any of its rights or obligations hereunder to any other person or entity without the prior written consent of the Investors.
(b)    Entire Agreement.  This Agreement and the Certificate of Designation, including the Schedules and Exhibits hereto constitute the entire understanding between the parties hereto with respect to the subject matter hereof and may be amended only by written execution by both parties.  Upon execution by the Company and the Investors, this Agreement shall be binding on each of the parties hereto.
(c)    Consent To Jurisdiction.  THIS AGREEMENT SHALL BE ENFORCED, GOVERNED AND CONSTRUED IN ALL RESPECTS IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO ITS CONFLICTS OF LAWS PRINCIPLES OTHER THAN SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF SUCH STATE.  FURTHERMORE, THE INVESTOR HEREBY IRREVOCABLY SUBMITS TO THE JURISDICTION OF THE FEDERAL OR STATE COURTS LOCATED IN THE STATE OF NEW YORK IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.  EACH OF THE COMPANY AND THE INVESTORS (AND, TO THE EXTENT PERMITTED BY LAW, ON BEHALF OF ITS AND THEIR EQUITY HOLDERS AND CREDITORS) HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY.
(d)    Notices.  Any notice, request or other communication to be given or made under this Agreement shall be in writing.  Such notice, request or other communication shall be deemed to have been duly given or made when it shall be delivered by hand, overnight mail, international courier (confirmed by facsimile), electronic mail or facsimile to the Party to which it is required or permitted to be given or made at such Party’s address specified below or at such other address as such Party shall have designated by notice to the other Parties.
If to the Borrower:
Alimera Sciences, Inc.  
    6210 Windward Parkway, Suite 290 
    Alpharetta, GA  30005 
    E-mail: rick.eiswirth@alimerasciences.com 
    Attention:  Richard S. Eiswirth, Jr., Chief Financial Officer and Chief Operating Officer

    
11

With a copy to:
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP 
One Marina Park Drive, Suite 900 
Boston, MA 02210 
Fax:  (617) 648-9199 
Email: ggriner@gunder.com 
Attn:  Gregg A. Griner, Esq.
If to the Purchasers:
Deerfield Management Company, L.P.
780 Third Avenue, 37th Floor
New York, NY 10017
Fax: (212) 599-3075
Email: dclark@deerfield.com
Attn: David J. Clark

With a copy to:
Katten Muchin Rosenman LLP 
575 Madison Avenue 
New York, New York 10022 
Fax:  (212) 940-8776 
Email:  mark.fisher@kattenlaw.com 
Attn:  Mark I. Fisher, Esq.

or to such other Person at such other place as the parties shall designate to one another in writing.
(e)    Counterparts.  This Agreement maybe executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one in the same agreement.  
(f)    Telecopy Execution and Delivery.  A facsimile, electronic mail, telecopy, PDF or other reproduction of this Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties by facsimile, e-mail or similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes.  At the request of any party, all parties agree to execute an original of 

    
12

this Agreement as well as any facsimile, telecopy or reproduction thereof.  The parties hereto hereby agree that neither shall raise the execution of facsimile, telecopy, PDF or other reproduction of this Agreement, or the fact that any signature or document was transmitted or communicated by facsimile, e-mail or similar electronic transmission device, as a defense to the formation of this Agreement.

[Signature pages follow]

    
13

IN WITNESS WHEREOF, the Investors and the Company have caused this Agreement to be duly executed as of the 26th day of November, 2014.

	
	
	COMPANY:

	 

	ALIMERA SCIENCES, INC.

	 

	 

	By: /s/ Richard S. Eiswirth, Jr.   

	Name: Richard S. Eiswirth, Jr.

	Title: Chief Operating Officer and Chief Financial Officer

	 

	 

	INVESTORS:

	DEERFIELD PRIVATE DESIGN FUND II, L.P.
By:  Deerfield Mgmt., L.P., General Partner 
By:  J.E. Flynn Capital, LLC, General Partner
By: /s/ David J. Clark            
Name:  David J. Clark
Title:    Authorized Signatory

	DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.
By:  Deerfield Mgmt., L.P., General Partner 
By:  J.E. Flynn Capital, LLC, General Partner
By: /s/ David J. Clark            
Name:  David J. Clark
Title:    Authorized Signatory

	DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By:  Deerfield Mgmt., L.P., General Partner 
By:  J.E. Flynn Capital, LLC, General Partner
By: /s/ David J. Clark            
Name:  David J. Clark
Title:    Authorized Signatory

    
 [Signature Page to Securities Purchase Agreement]

	
	
	DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.
By:  Deerfield Mgmt., L.P., General Partner 
By:  J.E. Flynn Capital, LLC, General Partner
By: /s/ David J. Clark            
Name:  David J. Clark
Title:    Authorized Signatory

	DEERFIELD PRIVATE DESIGN FUND III, L.P.
By:  Deerfield Mgmt. III, L.P., General Partner 
By:  J.E. Flynn Capital III, LLC, General Partner
By: /s/ David J. Clark            
Name:  David J. Clark
Title:    Authorized Signatory

    
 [Signature Page to Securities Purchase Agreement]

Schedule 1

Purchase Price Per Share of Series B Preferred Stock    $6,030

	
						
	Name of Investor
	 
	Aggregate 
Purchase Price
	Number 
of Shares of 
Series B 
Preferred Stock 
to be 
Purchased 
by Investor 
Pursuant to Section 2(a)*
	Number 
of Shares of 
Series B 
Preferred 
Stock 
to be 
Issued to Investor Pursuant to Section 2(b)*
	Total 
Investor Shares*

	Deerfield Private Design  
  Fund II, L.P.
	$
	10,485,000
	1,738.806
	26.082
	1,764.888

	Deerfield Private Design   
  International II, L.P.
	$
	12,015,000
	1,992.537
	29.888
	2,022.425

	Deerfield Private Design  
  Fund III, L.P.
	$
	22,500,000
	3,731.343
	55.970
	3,787.313

	Deerfield Special   
  Situations Fund, L.P.
	$
	2,730,000
	452.736
	6.791
	459.527

	Deerfield Special Situations 
  Fund International Limited
	$
	 2,270,000
	   376.451
	    5.647
	    382.098

	   Total:
	$
	50,000,000
	8,291.873*
	124.378
	8,416.251

_____________
*  Each share of Series B Preferred Stock is convertible into 1,000 shares of Common Stock.

    

Exhibit A

[Certificate of Designation]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]